Biotech
Commented by André Will-Laudien on July 3rd, 2023 | 07:45 CEST
Forget the heating law - 100% turnaround opportunity possible with Deutsche Bank, Volkswagen, BYD and Cardiol Therapeutics
When the major indices perform, some stocks unfortunately fall by the wayside. This can be due to a lack of attractiveness or the impact of megatrends such as Artificial Intelligence or Digitalization. Deutsche Bank is well on track for 2023, Volkswagen's low valuation is bound to attract attention at some point, and biotech company Cardiol Therapeutics is poised for a big jump. We take a closer look.
Read
Commented by André Will-Laudien on June 30th, 2023 | 07:30 CEST
Doublers are possible! Bayer, Defence Therapeutics, BioNTech, Valneva - It is hard to believe!
In 2022, a total of 19.5 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. However, thanks to growing research successes, there is hope that biotechnology will significantly increase the chances of survival for those affected. It is a matter of developing suitable active substances and launching modern therapies. mRNA technology has recently made a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. We are on the lookout for doubling potential.
Read
Commented by Armin Schulz on June 26th, 2023 | 09:20 CEST
Bayer, BioNxt Solutions, BioNTech - Biotech facing a rebound?
Due to the Corona pandemic, the pharmaceutical and biotech sector received a lot of attention. Many investors invested too late and could hardly benefit from the significant upward movements. After the hype, a sense of disillusionment set in. The vaccine manufacturers felt the effects because as soon as the pandemic subsided, the stock market also went down. Large and small companies experienced sell-offs, with some trading below their cash reserves. These low prices led to a wave of takeovers. Most recently, Novartis snapped up the biotech company Chinook for up to USD 3.5 billion. Therefore, today, we look at three companies from the healthcare sector.
Read
Commented by Stefan Feulner on June 26th, 2023 | 08:50 CEST
Best conditions for a summer rally - Defence Therapeutics, SMA Solar, Rheinmetall
The German stock market reflects the current weather situation - bright to cloudy, with occasional dark clouds moving in, bringing thunderstorms and heavy rain. In the past few days, lightning struck companies such as Helma Eigenheimbau, Siemens Energy and Lanxess, which was reflected in price losses of well over 10%. Other companies were spared from the storm front and should continue to enjoy their place in the sun due to the positive news.
Read
Commented by Fabian Lorenz on June 21st, 2023 | 08:40 CEST
Biotech comeback! Profit with BioNTech, Morphosys and BioNxt Solutions
Biotech shares have not been among the favourites on the stock market in recent months. After the Corona hype, they were overshadowed by BigTech and especially AI. Sartorius, BioNTech and Co. have corrected strongly. But in the meantime, there are strong signs of a comeback - led by Morphosys. The share of the German biotech veteran has doubled since the beginning of April. MediGene and Evotec have also recorded price jumps. Are BioNTech and BioNxt Solutions next? Morphosys also continues to be praised by analysts. But Goldman Sachs wants to end the party.
Read
Commented by Fabian Lorenz on June 14th, 2023 | 07:00 CEST
Evotec, Morphosys, Defence Therapeutics: Strong biotech stocks
When thinking of strong biotech stocks in recent years, BioNTech likely came to mind initially. With the successful development of the COVID-19 vaccine, the Mainz-based company advanced to become the new industry high-flyer. But in the meantime, the Company has come back to reality. The coffers are bulging, but vaccine revenues are falling, and the development of the cancer pipeline will still take several years. Therefore, Evotec and Morphosys are currently celebrating a comeback. Analysts are hailing Evotec as the "Tesla of biotech," and price targets are rising. The Morphosys share has increased by more than 100% this year, and analysts believe the value is capable of even more. Due to positive news, investors can speculate on a rebound with Defence Therapeutics.
Read
Commented by Nico Popp on June 12th, 2023 | 08:00 CEST
Disruption! From now on, everything will be different: PayPal, BYD, BioNXt
What is now called disruption in the startup scene has always existed. It refers to creative destruction, cutting old ties and rethinking things from the ground up. Companies that create marketable products in this way have an edge over the competition - and score points on the market with their uniqueness. We present three titles.
Read
Commented by Stefan Feulner on June 6th, 2023 | 07:15 CEST
MediGene, BioNTech, BioNxt Solutions - New opportunities after the correction
Acquisitions by big pharma were increasingly expected in the biotechnology sector last year, but these largely failed to materialize. However, this trend could accelerate in the current year. On the one hand, pharmaceutical companies, such as the vaccine manufacturer Pfizer, have deep pockets and need new innovations for their product portfolio. On the other hand, second-tier stocks are attractive targets due to the strong correction.
Read
Commented by Fabian Lorenz on June 1st, 2023 | 08:45 CEST
JinkoSolar, BioNTech and First Phosphate with important updates: This is what moves the shares
The energy transition is moving forward. In Germany, the traffic light government seems to have agreed on a new heating law. In the US, the agreement between Democrats and Republicans on the debt ceiling is a good sign for the industry because the promotion of environmentally friendly technologies depends on it. JinkoSolar and First Phosphate, among others, should benefit from this. Both companies have published important updates. There is also important news at BioNTech. However, these are not so positive. When will there be new impulses for the share?
Read
Commented by André Will-Laudien on May 31st, 2023 | 08:30 CEST
Biotech in turnaround mode! BioNTech, Defence Therapeutics, MorphoSys, Formycon - Take a close look at these shares!
Since the major pandemic wave in the biotech sector, most industry players have had to come to terms with normality again. Scolded investors quickly learned their lesson and are now looking warily at an industry that experienced its heyday between 2019 and 2021. Today, it is no longer the small announcements of hope that lead to significant price swings. After months of sell-offs, however, the sector is stabilizing for the first time, and some protagonists can report minor progress. When the sector trend weakens, selection is the trump card. Here are some suggestions.
Read